Live Attenuated Influenza Vaccine in Children

Seminars in Pediatric Infectious Diseases

Volumn 17, Issue 4, 2006, Pages 206-212

  Ambrose, Christopher S ^a   Walker, Robert E ^a   Connor, Edward M ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INFLUENZA VACCINE; LIVE VACCINE; PLACEBO;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; ASTHMA; CLINICAL TRIAL; COMPARATIVE STUDY; DECREASED APPETITE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INJECTION SITE REACTION; NONHUMAN; NOSE CONGESTION; RHINORRHEA; RISK BENEFIT ANALYSIS; VACCINATION REACTION; VIRUS STRAIN; WHEEZING;

ADMINISTRATION, INTRANASAL; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, ATTENUATED;

EID: 33749994704     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.spid.2006.08.007     Document Type: Article

References (56)

1. Couch R.B. Influenza: prospects for control. Ann Intern Med 133 (2000) 992-998
2. Thompson W.W., Shay D.K., Weintraub E., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
3. Piedra P.A., Gaglani M.J., Kozinetz C.A., et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23 (2005) 1540-1548
4. Monto A.S., and Sullivan K.M. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 110 (1993) 145-160
5. Neuzil K.M., Hohlbein C., and Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 156 (2002) 986-991
6. Glezen W.P., and Couch R.B. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 298 (1978) 587-592
7. Thompson W.W., Shay D.K., Weintraub E., et al. Influenza-associated hospitalizations in the United States. J Amer Med Assoc 292 (2004) 1333-1340
8. Bhat N., Wright J., Broder K., et al. Influenza-associated deaths among children in the United States, 2003-2004. N Eng J Med 353 (2005) 2559-2567
9. Poehling K.A., Edwards K.M., Weinberg G.A., et al. The underrecognized burden of influenza in young children. N Eng J Med 355 (2006) 31-40
10. Reichert T.A., Sugaya N., Fedson D.S., et al. The Japanese experience with vaccinating schoolchildren against influenza. N Eng J Med 344 (2001) 889-896
11. Monto A.S., Davenport F.M., Napier J.A., et al. Modification of an outbreak of influenza in Tecumseh, Michigan, by vaccination of schoolchildren. J Infect Dis 122 (1970) 16-25
12. Smith N.M., Bresee J.S., Shay D.K., et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55 (2006) 1-42
13. Block S.L., Reisinger K., Hultquist M., et al. Comparative immunogenicity of frozen and refrigerator-stable formulations of live attenuated influenza vaccine in healthy subjects (2006) Abstract of the Pediatric Academic Societies' 2006 Annual Meeting. San Francisco, CA, (abstr 752850)
14. Couch R.B., and Kasel J.A. Immunity to influenza in man. Annu Rev Microbiol 37 (1983) 529-549
15. Murphy B.R., and Clements M.L. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 146 (1989) 107-116
16. Cox R.J., Brokstad K.A., and Ogra P. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59 (2004) 1-15
17. Johnson P.R., Feldman S., Thompson J.M., et al. Immunity to influenza A virus infection in young children: A comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 154 (1986) 121-127
18. Liew F.Y., Russell S.M., Appleyard G., et al. Crossprotection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immuno1 4 (1984) 350-356
19. Ramphal R., Cogliano R.C., Shands J.W.J., et al. Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun 25 (1979) 992-997
20. Kris R.M., Asofsky R., Evans C.B., et al. Protection and recovery in influenza virus-infected mice immunosuppressed with anti-IgM. J ImmunoI 134 (1985) 1230-1235
21. Gotch F., McMichael A., Smith G., et al. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 165 (1987) 408-416
22. McMichael A.J., Gotch F.M., Noble G.R., et al. Cytotoxic T-cell immunity to influenza. N Engl J Med 309 (1983) 13-17
23. Murasko D.M., Bernstein E.D., Gardner E.D., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 37 (2002) 427-439
24. Price G.E., Gaszewska-Mastarlarz A., and Moskophidis D. The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. J Virol 74 (2000) 3996-4003
25. Asahi-Ozaki Y., Yoshikawa T., Iwakura Y., et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 74 (2004) 328-335
26. Hurwitz E.S., Haber M., Chang A., et al. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis 182 (2000) 1218-1221
27. Belshe R.B., Mendelman P.M., Treanor J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 338 (1998) 1405-1412
28. Tam J., and Pan-Asian CAIV-T Pediatric Efficacy Trial Network. Efficacy and safety of a live attenuated, trivalent influenza vaccine (CAIV-T) in children living in South East Asia against community acquired culture-confirmed influenza (2005) Abstract of the Pediatric Academic Societies' 2005 Annual Meeting. Washington, DC, (abstr 728)
29. Vesikari T, Fleming DM, Aristegui JF, et al: Safety, Efficacy, and Effectiveness of Cold-Adapted Influenza Vaccine, Trivalent Against Community-Acquired, Culture-Confirmed Influenza in Young Children Attending Day Care. Pediatrics, in press
30. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136 (2000) 168-175
31. Gaglani M.J., Piedra P.A., Herschler G.B., et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A (H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 158 (2004) 65-73
32. Piedra P., Gaglani M., Kozinetz C., et al. Protection of live attenuated intranasal influenza vaccine-trivalent (FluMist) against pneumonia and influenza (P-I) in school-aged children in the 2003-2004 influenza Type A (H3N2) outbreak (2005) Abstract of the Pediatric Academic Societies' 2005 Annual Meeting. Washington, DC, (abstr 524)
33. Gaglani M.J., Piedra P.A., Herschler G.B., et al. Live attenuated influenza vaccine (LAIV) administration in schoolchildren coincident with the 2003-2004 outbreak provided herd immunity against a drifted influenza variant A/Fujian/411/2002 (H3N2) (2005) Abstract of the Pediatric Academic Societies' 2005 Annual Meeting. Washington, DC, (abstr LB-3)
34. King Jr. J.C., Cummings G.E., Stoddard J., et al. A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics 116 (2005) e868-e873
35. Ashkenazi S, Vertruyen A, Aristegui J, et al: Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J, in press
36. Fleming D, Crovari P, Wahn U, et al: Comparison of the efficacy and safety of live-attenuated cold-adapted influenza vaccine, trivalent with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J, in press
37. Halloran M.E., Longini Jr. I.M., Gaglani M.J., et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 158 (2003) 305-311
38. Bernstein D., Yan L., Treanor J., et al. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 22 (2003) 28-34
39. Belshe R.B., and Gruber W.C. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 19 (2000) S66-S71
40. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181 (2000) 1133-1137
41. Edwards K.M., Dupont W.D., Westrich M.K., et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169 (1994) 68-76
42. Treanor J.J., Kotloff K., Betts R.F., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18 (2000) 899-906
43. Mendelman P.M., Rappaport R., Cho I., et al. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an A/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J 23 (2004) 1053-1055
44. Belshe R.B. Current status of live attenuated influenza virus vaccine in the US. Virus Res 103 (2004) 177-185
45. Bergen R., Black S., Shinefield H., et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 23 (2004) 138-144
46. Belshe R.B., Nichol K.L., Black S.B., et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 39 (2004) 920-927
47. Vesikari T., Karvonen A., Korhonen T., et al. A Randomized, double-blind study of the safety, transmissibility, and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 25 (2000) 590-595
48. FluMist Prescribing Information, MedImmune, Inc.
49. King Jr. J.C., Treanor J., Fast P.E., et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 181 (2000) 725-728
50. King J.C., Fast P.E., Zangwill K.M., et al. Safety, vaccine virus shedding, and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus (HIV)-infected and noninfected children. Pediatr Infect Dis J 20 (2001) 1124-1131
51. Nachman S., and Levin M. Randomized trial of the safety and immunogenicity of live attenuated influenza vaccine (LAIV) vs. inactivated influenza vaccine (TIV) in HIV+ children (2006) Program and Abstract of Pediatric Academic Societies' 2006 Annual Meeting. San Francisco, CA, (abstr 750286)
52. Zangwill K.M., and Belshe R.B. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary of the new era of routine vaccination. Pediatr Infect Dis J 23 (2004) 189-200
53. Centers for Disease Control and Prevention. Update: influenza activity-United States and Worldwide, 1997-98 season, and Composition of the 1998-99 Influenza Vaccine. MMWR 47 (1998) 280-284
54. Centers for Disease Control and Prevention. Update: influenza activity-United States and Worldwide, 2000-01 Season, and Composition of the 2001-02 Influenza Vaccine. MMWR 50 (2001) 466-470
55. Centers for Disease Control and Prevention. Update: Influenza Activity-United States, 2003-04 season. MMWR 53 (2004) 284-287
56. Centers for Disease Control and Prevention. Update: Influenza Activity-United States and Worldwide, 2004-05 Season. MMWR 54 (2005) 631-634